Latest Publications

@article{prochazkova_single-cell_2024,

title = {Single-cell profiling of surface glycosphingolipids opens a new dimension for deconvolution of breast cancer intratumoral heterogeneity and phenotypic plasticity.},

author = {Jiřina Procházková and Radek Fedr and Barbora Hradilová and Barbora Kvokačková and Josef Slavík and Ondrej Kováč and Miroslav Machala and Pavel Fabian and Jiří Navrátil and Simona Kráčalíková and Monika Levková and Petra Ovesná and Jan Bouchal and Karel Souček},

doi = {10.1016/j.jlr.2024.100609},

issn = {1539-7262 0022-2275},

year  = {2024},

date = {2024-09-01},

journal = {Journal of lipid research},

volume = {65},

number = {9},

pages = {100609},

abstract = {Glycosylated sphingolipids (GSLs) are a diverse group of cellular lipids typically reported as being rare in normal mammary tissue. In breast cancer (BCa), GSLs have emerged as noteworthy markers associated with breast cancer stem cells, mediators of phenotypic plasticity, and contributors to cancer cell chemoresistance. GSLs are potential surface markers that can uniquely characterize the heterogeneity of the tumor microenvironment, including cancer cell subpopulations and epithelial-mesenchymal plasticity (EMP). In this study, mass spectrometry analyses of the total sphingolipidome in breast epithelial cells and their mesenchymal counterparts revealed increased levels of Gb3 in epithelial cells and significantly elevated GD2 levels in the mesenchymal phenotype. To elucidate if GSL-related epitopes on BCa cell surfaces reflect EMP and cancer status, we developed and rigorously validated a 12-color spectral flow cytometry panel. This panel enables the simultaneous detection of native GSL epitopes (Gb3, SSEA1, SSEA3, SSEA4, and GD2), epithelial-mesenchymal transition markers (EpCAM, TROP2, and CD9), and lineage markers (CD45, CD31, and CD90) at the single-cell level. Next, the established panel was used for the analysis of BCa primary tumors and revealed surface heterogeneity in SSEA1, SSEA3, SSEA4, GD2, and Gb3, indicative of native epitope presence also on non-tumor cells. These findings further highlighted the phenotype-dependent alterations in GSL surface profiles, with differences between epithelial and stromal cells in the tumor. This study provides novel insights into BCa heterogeneity, shedding light on the potential of native GSL-related epitopes as markers for EMP and cancer status in fresh clinical samples. The developed single-cell approach offers promising avenues for further exploration.},

note = {Place: United States},

keywords = {*Breast Neoplasms/metabolism/pathology, *Epithelial-Mesenchymal Transition, *Glycosphingolipids/metabolism/analysis, *Single-Cell Analysis/methods, Breast cancer, Epithelial Cells, Female, Glycosphingolipids, Humans, Phenotype, phenotypic plasticity, stromal-like cells, surface profiling},

pubstate = {published},

tppubtype = {article}

}

@article{besse_hiv-protease_2024,

title = {HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.},

author = {Andrej Besse and Lenka Sedlarikova and Lorina Buechler and Marianne Kraus and Chieh-Hsiang Yang and Nicol Strakova and Karel Soucek and Jiri Navratil and Marek Svoboda and Alana L. Welm and Markus Joerger and Christoph Driessen and Lenka Besse},

doi = {10.1038/s41416-024-02774-9},

issn = {1532-1827 0007-0920},

year  = {2024},

date = {2024-09-01},

journal = {British journal of cancer},

volume = {131},

number = {5},

pages = {918–930},

abstract = {BACKGROUND: Resistance to chemotherapy is a major problem in the treatment of patients with triple-negative breast cancer (TNBC). Preclinical data suggest that TNBC is dependent on proteasomes; however, clinical observations indicate that the efficacy of proteasome inhibitors in TNBC may be limited, suggesting the need for combination therapies. METHODS: We compared bortezomib and carfilzomib and their combinations with nelfinavir and lopinavir in TNBC cell lines and primary cells with regard to their cytotoxic activity, functional proteasome inhibition, and induction of the unfolded protein response (UPR). Furthermore, we evaluated the involvement of sXBP1, ABCB1, and ABCG2 in the cytotoxic activity of drug combinations. RESULTS: Carfilzomib, via proteasome β5 + β2 inhibition, is more cytotoxic in TNBC than bortezomib, which inhibits β5 + β1 proteasome subunits. The cytotoxicity of carfilzomib was significantly potentiated by nelfinavir or lopinavir. Carfilzomib with lopinavir induced endoplasmic reticulum stress and pro-apoptotic UPR through the accumulation of excess proteasomal substrate protein in TNBC in vitro. Moreover, lopinavir increased the intracellular availability of carfilzomib by inhibiting carfilzomib export from cells that express high levels and activity of ABCB1, but not ABCG2. CONCLUSION: Proteasome inhibition by carfilzomib combined with nelfinavir/lopinavir represents a potential treatment option for TNBC, warranting further investigation.},

note = {Place: England},

keywords = {*ATP Binding Cassette Transporter, *Bortezomib/pharmacology, *Drug Synergism, *HIV Protease Inhibitors/pharmacology, *Lopinavir/pharmacology, *Nelfinavir/pharmacology, *Oligopeptides/pharmacology, *Triple Negative Breast Neoplasms/drug therapy/pathology, *Unfolded Protein Response/drug effects, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Apoptosis/drug effects, ATP Binding Cassette Transporter, Cell Line, Endoplasmic Reticulum Stress/drug effects, Female, Humans, Member 2/metabolism/antagonists & inhibitors, Neoplasm Proteins/antagonists & inhibitors/metabolism, Proteasome Inhibitors/pharmacology, Subfamily B/metabolism, Subfamily G, Tumor, X-Box Binding Protein 1/metabolism/genetics},

pubstate = {published},

tppubtype = {article}

}

@article{hofmanova_complex_2021,

title = {Complex Alterations of Fatty Acid Metabolism and Phospholipidome Uncovered in Isolated Colon Cancer Epithelial Cells.},

author = {Jiřina Hofmanová and Josef Slavík and Miroslav Ciganek and Petra Ovesná and Zuzana Tylichová and Martina Karasová and Ondřej Zapletal and Nicol Straková and Jiřina Procházková and Jan Bouchal and Zdeněk Kolář and Jiří Ehrmann and Monika Levková and Zlatka Hušková and Pavel Skalický and Alois Kozubík and Miroslav Machala and Jan Vondráček},

doi = {10.3390/ijms22136650},

issn = {1422-0067},

year  = {2021},

date = {2021-06-01},

journal = {International journal of molecular sciences},

volume = {22},

number = {13},

abstract = {The development of colon cancer, one of the most common malignancies, is accompanied with numerous lipid alterations. However, analyses of whole tumor samples may not always provide an accurate description of specific changes occurring directly in tumor epithelial cells. Here, we analyzed in detail the phospholipid (PL), lysophospholipid (lysoPL), and fatty acid (FA) profiles of purified EpCAM(+) cells, isolated from tumor and adjacent non-tumor tissues of colon cancer patients. We found that a number of FAs increased significantly in isolated tumor cells, which also included a number of long polyunsaturated FAs. Higher levels of FAs were associated with increased expression of FA synthesis genes, as well as with altered expression of enzymes involved in FA elongation and desaturation, including particularly fatty acid synthase, stearoyl-CoA desaturase, fatty acid desaturase 2 and ELOVL5 fatty acid elongase 5 We identified significant changes in ratios of specific lysoPLs and corresponding PLs. A number of lysophosphatidylcholine and lysophosphatidylethanolamine species, containing long-chain and very-long chain FAs, often with high numbers of double bonds, were significantly upregulated in tumor cells. Increased de novo synthesis of very long-chain FAs, or, altered uptake or incorporation of these FAs into specific lysoPLs in tumor cells, may thus contribute to reprogramming of cellular phospholipidome and membrane alterations observed in colon cancer.},

note = {Place: Switzerland},

keywords = {*Gene Expression Regulation, *Lipid Metabolism, Adenocarcinoma/enzymology/genetics/*metabolism, Aged, Colonic Neoplasms/enzymology/genetics/*metabolism, colorectal carcinoma, desaturation, EpCAM, Epithelial Cells, Epithelial Cells/enzymology/metabolism, Fatty Acid Desaturases/genetics/metabolism, Fatty Acid Elongases/genetics/metabolism, Fatty Acid Synthases/genetics/metabolism, fatty acid synthesis, Fatty Acids/*metabolism, Female, Humans, lipidomics, Lipogenesis, lysophospholipids, Male, Neoplastic, Phospholipids, Phospholipids/*metabolism, Stearoyl-CoA Desaturase/genetics/metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{prochazkova_specific_2020,

title = {Specific alterations of sphingolipid metabolism identified in EpCAM-positive cells isolated from human colon tumors.},

author = {Jiřina Procházková and Josef Slavík and Jan Bouchal and Monika Levková and Zlata Hušková and Jiří Ehrmann and Petra Ovesná and Zdeněk Kolář and Pavel Skalický and Nicol Straková and Ondřej Zapletal and Alois Kozubík and Jiřina Hofmanová and Jan Vondráček and Miroslav Machala},

doi = {10.1016/j.bbalip.2020.158742},

issn = {1879-2618 1388-1981},

year  = {2020},

date = {2020-09-01},

journal = {Biochimica et biophysica acta. Molecular and cell biology of lipids},

volume = {1865},

number = {9},

pages = {158742},

note = {Place: Netherlands},

keywords = {80 and over, Adult, Aged, B4GALTs, Colon adenocarcinoma, Colorectal Neoplasms/*metabolism, EPCAM-positive cells, Epithelial Cell Adhesion Molecule/*metabolism, Female, Galactosyltransferases/genetics, Humans, Lactosylceramide, Male, Middle Aged, Sphingolipid metabolism, Sphingolipids/*metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{remsik_tgf-_2020,

title = {TGF-β regulates Sca-1 expression and plasticity of pre-neoplastic mammary epithelial stem cells.},

author = {Ján Remšík and Markéta Pícková and Ondřej Vacek and Radek Fedr and Lucia Binó and Aleš Hampl and Karel Souček},

doi = {10.1038/s41598-020-67827-4},

issn = {2045-2322},

year  = {2020},

date = {2020-07-01},

journal = {Scientific reports},

volume = {10},

number = {1},

pages = {11396},

abstract = {The epithelial-mesenchymal plasticity, in tight association with stemness, contributes to the mammary gland homeostasis, evolution of early neoplastic lesions and cancer dissemination. Focused on cell surfaceome, we used mouse models of pre-neoplastic mammary epithelial and cancer stem cells to reveal the connection between cell surface markers and distinct cell phenotypes. We mechanistically dissected the TGF-β family-driven regulation of Sca-1, one of the most commonly used adult stem cell markers. We further provided evidence that TGF-β disrupts the lineage commitment and promotes the accumulation of tumor-initiating cells in pre-neoplastic cells.},

note = {Place: England},

keywords = {Animal/pathology, Animals, Ataxin-1/*metabolism, Breast Neoplasms/genetics/*pathology, Cell Line, Cell Plasticity/genetics, Epithelial Cells/pathology, Epithelial-Mesenchymal Transition/genetics, ErbB-2/genetics, Experimental/genetics/*pathology, Female, Gene Expression Regulation, Humans, Mammary Glands, Mammary Neoplasms, Mice, Neoplastic, Neoplastic Stem Cells/*pathology, Receptor, Recombinant Proteins/genetics/metabolism, Signal Transduction/genetics, Transforming Growth Factor beta/genetics/*metabolism, Tumor/transplantation},

pubstate = {published},

tppubtype = {article}

}

@article{nekvindova_hepatocellular_2020,

title = {Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450.},

author = {Jana Nekvindova and Alena Mrkvicova and Veronika Zubanova and Alena Hyrslova Vaculova and Pavel Anzenbacher and Pavel Soucek and Lenka Radova and Ondrej Slaby and Igor Kiss and Jan Vondracek and Alena Spicakova and Lucia Bohovicova and Pavel Fabian and Zdenek Kala and Vladimir Palicka},

doi = {10.1016/j.bcp.2020.113912},

issn = {1873-2968 0006-2952},

year  = {2020},

date = {2020-07-01},

journal = {Biochemical pharmacology},

volume = {177},

pages = {113912},

abstract = {Hepatocellular carcinoma (HCC) remains a highly prevalent and deadly disease, being among the top causes of cancer-related deaths worldwide. Despite the fact that the liver is the major site of biotransformation, studies on drug metabolizing enzymes in HCC are scarce. It is known that malignant transformation of hepatocytes leads to a significant alteration of their metabolic functions and overall deregulation of gene expression. Advanced stages of the disease are thus frequently associated with liver failure, and severe alteration of drug metabolism. However, the impact of dysregulation of metabolic enzymes on therapeutic efficacy and toxicity in HCC patients is largely unknown. Here we demonstrate a significant down-regulation in European Caucasian patients of cytochromes P450 (CYPs), the major xenobiotic-metabolizing enzymes, in HCC tumour samples as compared to their surrounding non-cancerous (reference) tissue. Moreover, we report for the first time the association of the unique CYP profiles with specific transcriptome changes, and interesting correlations with expression levels of nuclear receptors and with the histological grade of the tumours. Integrated analysis has suggested certain co-expression profiles of CYPs with lncRNAs that need to be further characterized. Patients with large tumours with down-regulated CYPs could be more vulnerable to drug toxicity; on the other hand, such tumours would eliminate drugs more slowly and should be more sensitive to pharmacotherapy (except in the case of pro-drugs where activation is necessary).},

note = {Place: England},

keywords = {*Gene Expression Regulation, *Transcriptome, Adult, Aged, Carcinoma, Cohort Studies, CYP, Cytochrome P-450 Enzyme System/*genetics, Cytochrome P450, Cytoplasmic and Nuclear/genetics/metabolism, Drug metabolism, Enzymologic, Female, Gene Expression, Gene Expression Profiling, Hepatocellular carcinoma, Hepatocellular/*enzymology/pathology, Hepatocytes/metabolism, Humans, Inactivation, Liver Neoplasms/*enzymology/pathology, Liver/metabolism, Male, Metabolic/genetics, Middle Aged, Neoplasm Grading, Non-coding RNA, Receptors},

pubstate = {published},

tppubtype = {article}

}

@article{boudny_novel_2019,

title = {Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.},

author = {Miroslav Boudny and Jana Zemanova and Prashant Khirsariya and Marek Borsky and Jan Verner and Jana Cerna and Alexandra Oltova and Vaclav Seda and Marek Mraz and Josef Jaros and Zuzana Jaskova and Michaela Spunarova and Yvona Brychtova and Karel Soucek and Stanislav Drapela and Marie Kasparkova and Jiri Mayer and Kamil Paruch and Martin Trbusek},

doi = {10.3324/haematol.2018.203430},

issn = {1592-8721 0390-6078},

year  = {2019},

date = {2019-12-01},

journal = {Haematologica},

volume = {104},

number = {12},

pages = {2443–2455},

abstract = {Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is, therefore, of critical importance. Here we report details of the anti-chronic lymphocytic leukemia single-agent activity of MU380, our recently identified potent, selective, and metabolically robust inhibitor of checkpoint kinase 1. We also describe a newly developed enantioselective synthesis of MU380, which allows preparation of gram quantities of the substance. Checkpoint kinase 1 is a master regulator of replication operating primarily in intra-S and G(2)/M cell cycle checkpoints. Initially tested in leukemia and lymphoma cell lines, MU380 significantly potentiated efficacy of gemcitabine, a clinically used inducer of replication stress. Moreover, MU380 manifested substantial single-agent activity in both TP53-wild type and TP53-mutated leukemia and lymphoma cell lines. In chronic lymphocytic leukemia-derived cell lines MEC-1, MEC-2 (both TP53-mut), and OSU-CLL (TP53-wt) the inhibitor impaired cell cycle progression and induced apoptosis. In primary clinical samples, MU380 used as a single-agent noticeably reduced the viability of unstimulated chronic lymphocytic leukemia cells as well as those induced to proliferate by anti-CD40/IL-4 stimuli. In both cases, effects were comparable in samples harboring p53 pathway dysfunction (TP53 mutations or ATM mutations) and TP53-wt/ATM-wt cells. Lastly, MU380 also exhibited significant in vivo activity in a xenotransplant mouse model (immunodeficient strain NOD-scid IL2Rγ(null) ) where it efficiently suppressed growth of subcutaneous tumors generated from MEC-1 cells.},

note = {Place: Italy},

keywords = {*Drug Synergism, *Mutation, Animals, Antimetabolites, Antineoplastic/pharmacology, Apoptosis, B-Cell/*drug therapy/genetics/pathology, Biomarkers, Cell Cycle, Cell Proliferation, Checkpoint Kinase 1/*antagonists & inhibitors, Chronic, Cultured, Deoxycytidine/analogs & derivatives/pharmacology, Drug resistance, Female, gemcitabine, Gene Expression Regulation, Humans, Inbred NOD, Leukemia, Lymphocytic, Mice, Neoplasm/drug effects, Neoplastic/*drug effects, Piperidines/*pharmacology, Protein Kinase Inhibitors/pharmacology, Pyrazoles/*pharmacology, Pyrimidines/*pharmacology, SCID, Tumor Cells, Tumor Suppressor Protein p53/*genetics, Tumor/genetics, Xenograft Model Antitumor Assays},

pubstate = {published},

tppubtype = {article}

}

@article{simek_lc-msms_2019,

title = {LC-MS/MS study of in vivo fate of hyaluronan polymeric micelles carrying doxorubicin.},

author = {Matěj Šimek and Martina Hermannová and Daniela Šmejkalová and Tereza Foglová and Karel Souček and Lucia Binó and Vladimír Velebný},

doi = {10.1016/j.carbpol.2018.12.104},

issn = {1879-1344 0144-8617},

year  = {2019},

date = {2019-04-01},

journal = {Carbohydrate polymers},

volume = {209},

pages = {181–189},

abstract = {A better understanding of in vivo behavior of nanocarriers is necessary for further improvement in their development. Here we present a novel approach, where both the matrix and the drug can be analyzed by LCMS/MS after one sample handling. The developed method was applied for the comparison of pharmacokinetic profile of free and encapsulated doxorubicin (DOX) in oleyl hyaluronan (HA-C18:1) polymeric micelles. The results indicated that nanocarriers were rapidly dissociated upon in vivo administration. Despite this fact, the administration of encapsulated DOX led to its longer circulation time and enhanced tumor targeting. This effect was not observed injecting blank HA-C18:1 micelles followed by unencapsulated DOX. Biodistribution studies and molecular weight estimation of the carrier matrix indicated relatively high stability of HA-C18:1 ester bond in bloodstream and complete elimination of the derivative within 72 h. The proposed methodology provides a novel strategy to elucidate the pharmacokinetic behavior of polysaccharide-based drug delivery systems.},

note = {Place: England},

keywords = {*Micelles, Animals, Biodistribution, Chromatography, Doxorubicin, Doxorubicin/*chemistry/pharmacokinetics, Drug Carriers/*chemistry, Drug Liberation, Female, Hyaluronan, Hyaluronic Acid/*chemistry, Liquid, Mice, Molecular Weight, Pharmacokinetics, Polymeric micelles, Tandem Mass Spectrometry, Tissue Distribution},

pubstate = {published},

tppubtype = {article}

}

@article{remsik_trop-2_2018,

title = {Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition.},

author = {Ján Remšík and Lucia Binó and Zuzana Kahounová and Gvantsa Kharaishvili and Šárka Šimecková and Radek Fedr and Tereza Kucírková and Sára Lenárt and Ximena Maria Muresan and Eva Slabáková and Lucia Knopfová and Jan Bouchal and Milan Král and Petr Beneš and Karel Soucek},

doi = {10.1093/carcin/bgy095},

issn = {1460-2180 0143-3334},

year  = {2018},

date = {2018-12-01},

journal = {Carcinogenesis},

volume = {39},

number = {11},

pages = {1411–1418},

abstract = {The cell surface glycoprotein Trop-2 is commonly overexpressed in carcinomas and represents an exceptional antigen for targeted therapy. Here, we provide evidence that surface Trop-2 expression is functionally connected with an epithelial phenotype in breast and prostate cell lines and in patient tumor samples. We further show that Trop-2 expression is suppressed epigenetically or through the action of epithelial-to-mesenchymal transition transcription factors and that deregulation of Trop-2 expression is linked with cancer progression and poor patient prognosis. Moreover, our data suggest that the cancer plasticity-driven intratumoral heterogeneity in Trop-2 expression may significantly contribute to response and resistance to therapies targeting Trop-2-expressing cells.},

note = {Place: England},

keywords = {Animals, Antigens, Breast Neoplasms/mortality/*pathology, Cadherins/biosynthesis, Carcinoma/*pathology, CD/biosynthesis, Cell Adhesion Molecules/genetics/*metabolism, Cell Line, Disease Progression, DNA Methylation/genetics, Epithelial Cells/*metabolism, Epithelial-Mesenchymal Transition/physiology, Female, Humans, Inbred BALB C, Male, Mice, Neoplasm/genetics/*metabolism, Prostatic Neoplasms/mortality/*pathology, Tumor, Xenograft Model Antitumor Assays},

pubstate = {published},

tppubtype = {article}

}

@article{soucek_presence_2018,

title = {Presence of growth/differentiation factor-15 cytokine in human follicular fluid, granulosa cells, and oocytes.},

author = {Karel Souček and Alice Malenovská and Zuzana Kahounová and Ján Remšík and Zuzana Holubcová and Tomáš Soukup and Daniela Kurfürstová and Jan Bouchal and Tereza Suchánková and Eva Slabáková and Aleš Hampl},

doi = {10.1007/s10815-018-1230-5},

issn = {1573-7330 1058-0468},

year  = {2018},

date = {2018-08-01},

journal = {Journal of assisted reproduction and genetics},

volume = {35},

number = {8},

pages = {1407–1417},

abstract = {PURPOSE: The purpose of the study was to determine whether the GDF-15 is present in follicular fluid; to evaluate if there is a relation between follicular and serum levels of GDF-15 and fertility status of study subjects; and to test whether granulosa cells, oocytes, or both produce GDF-15. METHODS: This study used follicular fluid (FF, serum, and oocytes obtained under informed consent from women undergoing oocyte retrieval for in vitro fertilization. It also used ovaries from deceased preterm newborns. Collection of FF and blood at the time of oocyte retrieval, ELISA and western blot were performed to determine levels and forms of GDF-15. Concentrations of GDF-15 in FF and serum, its expression in ovarian tissue, and secretion from granulosa cells were analyzed. RESULTS: GDF-15 concentration in FF ranged from 35 to 572 ng/ml, as determined by ELISA. Western blot analysis revealed the GDF-15 pro-dimer only in FF. Both normal healthy and cancerous granulosa cells secreted GDF-15 into culture media. Primary oocytes displayed cytoplasmic GDF-15 positivity in immunostained newborn ovaries, and its expression was also observed in fully grown human oocytes. CONCLUSIONS: To the best of our knowledge, this is the first documentation of cytokine GDF-15 presence in follicular fluid. Its concentration was not associated with donor/patient fertility status. Our data also show that GDF-15 is expressed and inducible in both normal healthy and cancerous granulosa cells, as well as in oocytes.},

note = {Place: Netherlands},

keywords = {Adult, Cell Differentiation/*genetics, Developmental, Female, Fertilization in Vitro, Follicular fluid, Follicular Fluid/*metabolism, Follicular granulosa cells, Gene Expression Regulation, Granulosa Cells/*metabolism, Growth Differentiation Factor 15/*genetics/isolation & purification, Growth/differentiation factor-15, Humans, IVF, Oocyte Retrieval, Oocytes/metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{strapacova_relative_2018,

title = {Relative effective potencies of dioxin-like compounds in rodent and human lung cell models.},

author = {Simona Strapáčová and Petra Brenerová and Pavel Krčmář and Patrik Andersson and Karin I. Ede and Majorie B. M. Duursen and Martin Berg and Jan Vondráček and Miroslav Machala},

doi = {10.1016/j.tox.2018.05.004},

issn = {1879-3185 0300-483X},

year  = {2018},

date = {2018-07-01},

journal = {Toxicology},

volume = {404-405},

pages = {33–41},

abstract = {Toxicity of dioxin-like compounds (DLCs), such as polychlorinated dibenzo-p-dioxins, dibenzofurans and biphenyls, is largely mediated via aryl hydrocarbon receptor (AhR) activation. AhR-mediated gene expression can be tissue-specific; however, the inducibility of AhR in the lungs, a major target of DLCs, remains poorly characterized. In this study, we developed relative effective potencies (REPs) for a series of DLCs in both rodent (MLE-12, RLE-6TN) and human (A549, BEAS-2B) lung and bronchial epithelial cell models, using expression of both canonical (CYP1A1, CYP1B1) and less well characterized (TIPARP, AHRR, ALDH3A1) AhR target genes. The use of rat, murine and human cell lines allowed us to determine both species-specific differences in sensitivity of responses to DLCs in lung cellular models and deviations from established WHO toxic equivalency factor values (TEF) values. Finally, expression of selected AhR target genes was determined in vivo, using lung tissues of female rats exposed to a single oral dose of DLCs and compared with the obtained in vitro data. All cell models were highly sensitive to DLCs, with murine MLE-12 cells being the most sensitive and human A549 cells being the least sensitive. Interestingly, we observed that four AhR target genes were more sensitive than CYP1A1 in lung cell models (CYP1B1, AHRR, TIPARP and/or ALDH3A1). We found some deviations, with strikingly low REPs for polychlorinated biphenyls PCBs 105, 167, 169 and 189 in rat RLE-6TN cells-derived REPs for a series of 20 DLCs evaluated in this study, as compared with WHO TEF values. For other DLCs, including PCBs 126, 118 and 156, REPs were generally in good accordance with WHO TEF values. This conclusion was supported by in vivo data obtained in rat lung tissue. However, we found that human lung REPs for 2,3,4,7,8-pentachlorodibenzofuran and PCB 126 were much lower than the respective rat lung REPs. Furthermore, PCBs 118 and 156 were almost inactive in these human cells. Our observations may have consequences for risk assessment. Given the differences observed between rat and human data sets, development of human-specific REP/TEFs, and the use of CYP1B1, AHRR, TIPARP and/or ALDH3A1 mRNA inducibility as sensitive endpoints, are recommended for assessment of relative effective potencies of DLCs.},

note = {Place: Ireland},

keywords = {A549 Cells, Acute/methods, AhR, Animals, Dioxin-like compounds, Dioxins/*toxicity, Dose-Response Relationship, Drug, Endogenous target genes, Female, Humans, Lung epithelial cells, Lung/*drug effects/metabolism/*pathology, Mice, Rats, Relative effective potencies, Rodentia, Species Specificity, Sprague-Dawley, Toxicity Tests},

pubstate = {published},

tppubtype = {article}

}

@article{kahounova_fibroblast_2018,

title = {The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition.},

author = {Zuzana Kahounová and Daniela Kurfürstová and Jan Bouchal and Gvantsa Kharaishvili and Jiří Navrátil and Ján Remšík and Šárka Šimečková and Vladimír Študent and Alois Kozubík and Karel Souček},

doi = {10.1002/cyto.a.23101},

issn = {1552-4930 1552-4922},

year  = {2018},

date = {2018-07-01},

journal = {Cytometry. Part A : the journal of the International Society for Analytical Cytology},

volume = {93},

number = {9},

pages = {941–951},

abstract = {The identification of fibroblasts and cancer-associated fibroblasts from human cancer tissue using surface markers is difficult, especially because the markers used currently are usually not expressed solely by fibroblasts, and the identification of fibroblast-specific surface molecules is still under investigation. It was aimed to compare three commercially available antibodies in the detection of different surface epitopes of fibroblasts (anti-fibroblast, fibroblast activation protein α, and fibroblast surface protein). The specificity of their expression, employing fibroblast cell lines and tumor-derived fibroblasts from breast and prostate tissues was investigated. Both the established fibroblast cell line HFF-1 and ex vivo primary fibroblasts isolated from breast and prostate cancer tissues expressed the tested surface markers to different degrees. Surprisingly, those markers were expressed also by permanent cell lines of epithelial origin, both benign and cancer-derived (breast-cell lines MCF 10A, HMLE and prostate-cell lines BPH-1, DU 145, and PC-3). The expression of fibroblast activation protein α increased on the surface of previously described models of epithelial cells undergoing epithelial-to-mesenchymal transition in response to treatment with TGF-β1. To prove the co-expression of the fibroblast markers on cells of epithelial origin, we used freshly dissociated human prostate and breast cancer tissues. The results confirmed the co-expression of anti-fibroblast and fibroblast surface protein on CD31/CD45-negative/EpCAM-positive epithelial cells. In summary, our data support the findings that the tested fibroblast markers are not fibroblast specific and may be expressed also by cells of epithelial origin (e.g., cells undergoing EMT). Therefore, the expression of these markers should be interpreted with caution, and the combination of several epitopes for both positive (anti-fibroblast or fibroblast activation protein α) and negative (EpCAM) identification of fibroblasts from breast and prostate tumor tissues is advised. © 2017 International Society for Advancement of Cytometry.},

note = {Place: United States},

keywords = {anti-fibroblast, Biomarkers/*metabolism, Breast Neoplasms/metabolism, cancer-associated fibroblasts, Cell Line, Endopeptidases, Epithelial Cell Adhesion Molecule/metabolism, Epithelial Cells/metabolism, Epithelial-Mesenchymal Transition/*physiology, epithelial-to-mesenchymal transition, Female, fibroblast activation protein α, fibroblast surface protein, Fibroblasts/*metabolism, Gelatinases/*metabolism, Humans, Leukocyte Common Antigens/metabolism, Male, Membrane Proteins/*metabolism, PC-3 Cells, Platelet Endothelial Cell Adhesion Molecule-1/metabolism, Prostatic Neoplasms/metabolism, Serine Endopeptidases/*metabolism, Transforming Growth Factor beta1/metabolism, Tumor},

pubstate = {published},

tppubtype = {article}

}

@article{remsik_plasticity_2018,

title = {Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer.},

author = {Ján Remšík and Radek Fedr and Jiří Navrátil and Lucia Binó and Eva Slabáková and Pavel Fabian and Marek Svoboda and Karel Souček},

doi = {10.1038/bjc.2017.497},

issn = {1532-1827 0007-0920},

year  = {2018},

date = {2018-03-01},

journal = {British journal of cancer},

volume = {118},

number = {6},

pages = {813–819},

abstract = {Background:The intratumoural heterogeneity, often driven by epithelial-to-mesenchymal transition (EMT), significantly contributes to chemoresistance and disease progression in adenocarcinomas. Methods:We introduced a high-throughput screening platform to identify surface antigens that associate with epithelial–mesenchymal plasticity in well-defined pairs of epithelial cell lines and their mesenchymal counterparts. Using multicolour flow cytometry, we then analysed the expression of 10 most robustly changed antigens and identified a 10-molecule surface signature, in pan-cytokeratin-positive/EpCAM-positive and -negative fractions of dissociated breast tumours. Results:We found that surface CD9, CD29, CD49c, and integrin ß5 are lost in breast cancer cells that underwent EMT in vivo. The tetraspanin family member CD9 was concordantly downregulated both in vitro and in vivo and associated with epithelial phenotype and favourable prognosis. Conclusions:We propose that overall landscape of 10-molecule surface signature expression reflects the epithelial–mesenchymal plasticity in breast cancer.},

note = {Place: England},

keywords = {Antigens, Biomarkers, Breast Neoplasms/*genetics/*immunology/pathology, Cell Line, Cell Plasticity/immunology, Cellular Reprogramming/physiology, Epithelial-Mesenchymal Transition/immunology, Female, Flow Cytometry, Genetic, High-Throughput Screening Assays, Humans, Neoplasm Metastasis, Neoplasm/*biosynthesis/immunology, Surface/*biosynthesis/immunology, Tetraspanin 29/biosynthesis/immunology, Transcription, Tumor},

pubstate = {published},

tppubtype = {article}

}

@article{simkova_dual_2016,

title = {The dual role of asporin in breast cancer progression.},

author = {Dana Simkova and Gvantsa Kharaishvili and Gabriela Korinkova and Tomas Ozdian and Tereza Suchánková-Kleplová and Tomas Soukup and Michal Krupka and Adela Galandakova and Petr Dzubak and Maria Janikova and Jiri Navratil and Zuzana Kahounova and Karel Soucek and Jan Bouchal},

doi = {10.18632/oncotarget.10471},

issn = {1949-2553},

year  = {2016},

date = {2016-08-01},

journal = {Oncotarget},

volume = {7},

number = {32},

pages = {52045–52060},

abstract = {Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer. According to our in silico search, high asporin expresion associates with significantly better relapse free survival (RFS) in patients with low-grade tumors but RFS is significantly worse in patients with grade 3 tumors. In line with other studies, we have confirmed asporin expression by RNA scope in situ hybridization in cancer associated fibroblasts. We have also found asporin expression in the Hs578T breast cancer cell line which we confirmed by quantitative RT-PCR and western blotting. From multiple testing, we found that asporin can be downregulated by bone morphogenetic protein 4 while upregulation may be facilited by serum-free cultivation or by three dimensional growth in stiff Alvetex scaffold. Downregulation by shRNA inhibited invasion of Hs578T as well as of CAFs and T47D cells. Invasion of asporin-negative MDA-MB-231 and BT549 breast cancer cells through collagen type I was enhanced by recombinant asporin. Besides other investigations, large scale analysis of aspartic acid repeat polymorphism will be needed for clarification of the asporin dual role in progression of breast cancer.},

note = {Place: United States},

keywords = {3D cultivation, asporin, Breast cancer, Breast Neoplasms/metabolism/mortality/*pathology, Disease-Free Survival, Extracellular Matrix Proteins/*metabolism, Female, Fibroblasts/metabolism/pathology, grade, Humans, Kaplan-Meier Estimate, Prognosis, stiffness, Tumor Microenvironment/physiology},

pubstate = {published},

tppubtype = {article}

}

@article{slabakova_opposite_2015,

title = {Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.},

author = {Eva Slabáková and Gvantsa Kharaishvili and Monika Smějová and Zuzana Pernicová and Tereza Suchánková and Ján Remšík and Stanislav Lerch and Nicol Straková and Jan Bouchal and Milan Král and Zoran Culig and Alois Kozubík and Karel Souček},

doi = {10.18632/oncotarget.5392},

issn = {1949-2553},

year  = {2015},

date = {2015-11-01},

journal = {Oncotarget},

volume = {6},

number = {34},

pages = {36156–36171},

abstract = {Plasticity of cancer cells, manifested by transitions between epithelial and mesenchymal phenotypes, represents a challenging issue in the treatment of neoplasias. Both epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are implicated in the processes of metastasis formation and acquisition of stem cell-like properties. Mouse double minute (MDM) 2 and MDMX are important players in cancer progression, as they act as regulators of p53, but their function in EMT and metastasis may be contradictory. Here, we show that the EMT phenotype in multiple cellular models and in clinical prostate and breast cancer samples is associated with a decrease in MDM2 and increase in MDMX expression. Modulation of EMT-accompanying changes in MDM2 expression in benign and transformed prostate epithelial cells influences their migration capacity and sensitivity to docetaxel. Analysis of putative mechanisms of MDM2 expression control demonstrates that in the context of defective p53 function, MDM2 expression is regulated by EMT-inducing transcription factors Slug and Twist. These results provide an alternative context-specific role of MDM2 in EMT, cell migration, metastasis, and therapy resistance.},

note = {Place: United States},

keywords = {Animals, Breast Neoplasms/genetics/*metabolism/pathology, Cell Cycle Proteins, Cell Line, Epithelial-Mesenchymal Transition, Epithelial-Mesenchymal Transition/*physiology, Female, Heterografts, Humans, Male, MDM2/MDMX, Mice, Nuclear Proteins/*biosynthesis, Nude, Phenotype, prostate/breast cancer, Prostatic Neoplasms/genetics/*metabolism/pathology, Proto-Oncogene Proteins c-mdm2/*biosynthesis, Proto-Oncogene Proteins/*biosynthesis, Snai2/Slug, Transfection, Tumor, TWIST},

pubstate = {published},

tppubtype = {article}

}

@article{kratochvilova_tumor_2015,

title = {Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.},

author = {Kateřina Kratochvílová and Peter Horak and Milan Ešner and Karel Souček and Dietmar Pils and Mariam Anees and Erwin Tomasich and František Dráfi and Veronika Jurtíková and Aleš Hampl and Michael Krainer and Petr Vaňhara},

doi = {10.1002/ijc.29502},

issn = {1097-0215 0020-7136},

year  = {2015},

date = {2015-09-01},

journal = {International journal of cancer},

volume = {137},

number = {6},

pages = {1330–1340},

abstract = {Ovarian cancer is one of the most common malignancies in women and contributes greatly to cancer-related deaths. Tumor suppressor candidate 3 (TUSC3) is a putative tumor suppressor gene located at chromosomal region 8p22, which is often lost in epithelial cancers. Epigenetic silencing of TUSC3 has been associated with poor prognosis, and hypermethylation of its promoter provides an independent biomarker of overall and disease-free survival in ovarian cancer patients. TUSC3 is localized to the endoplasmic reticulum in an oligosaccharyl tranferase complex responsible for the N-glycosylation of proteins. However, the precise molecular role of TUSC3 in ovarian cancer remains unclear. In this study, we establish TUSC3 as a novel ovarian cancer tumor suppressor using a xenograft mouse model and demonstrate that loss of TUSC3 alters the molecular response to endoplasmic reticulum stress and induces hallmarks of the epithelial-to-mesenchymal transition in ovarian cancer cells. In summary, we have confirmed the tumor-suppressive function of TUSC3 and identified the possible mechanism driving TUSC3-deficient ovarian cancer cells toward a malignant phenotype.},

note = {Place: United States},

keywords = {Animals, Cell Line, Endoplasmic Reticulum Stress, Endoplasmic Reticulum Stress/*genetics, Epithelial-Mesenchymal Transition/*genetics, epithelial-to-mesenchymal transition, Female, Genes, Heterografts, Humans, Inbred NOD, Membrane Proteins/*genetics, Mice, N33, ovarian cancer, Ovarian Neoplasms/*genetics, SCID, Tumor, Tumor Suppressor, Tumor Suppressor Proteins/*genetics, Tumor Suppressor/physiology, TUSC3},

pubstate = {published},

tppubtype = {article}

}

@article{knopfova_c-myb_2012,

title = {c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for matrix-dependent breast cancer cell invasion and metastasis.},

author = {Lucia Knopfová and Petr Beneš and Lucie Pekarčíková and Markéta Hermanová and Michal Masařík and Zuzana Pernicová and Karel Souček and Jan Smarda},

doi = {10.1186/1476-4598-11-15},

issn = {1476-4598},

year  = {2012},

date = {2012-03-01},

journal = {Molecular cancer},

volume = {11},

pages = {15},

abstract = {BACKGROUND: The c-Myb transcription factor is essential for the maintenance of stem-progenitor cells in bone marrow, colon epithelia, and neurogenic niches. c-Myb malfunction contributes to several types of malignancies including breast cancer. However, the function of c-Myb in the metastatic spread of breast tumors remains unexplored. In this study, we report a novel role of c-Myb in the control of specific proteases that regulate the matrix-dependent invasion of breast cancer cells. RESULTS: Ectopically expressed c-Myb enhanced migration and ability of human MDA-MB-231 and mouse 4T1 mammary cancer cells to invade Matrigel but not the collagen I matrix in vitro. c-Myb strongly increased the expression/activity of cathepsin D and matrix metalloproteinase (MMP) 9 and significantly downregulated MMP1. The gene coding for cathepsin D was suggested as the c-Myb-responsive gene and downstream effector of the migration-promoting function of c-Myb. Finally, we demonstrated that c-Myb delayed the growth of mammary tumors in BALB/c mice and affected the metastatic potential of breast cancer cells in an organ-specific manner. CONCLUSIONS: This study identified c-Myb as a matrix-dependent regulator of invasive behavior of breast cancer cells.},

note = {Place: England},

keywords = {Animals, Breast Neoplasms/genetics/*metabolism, Cathepsin D/genetics/*metabolism, Cell Line, Cell Movement/genetics/physiology, Electrophoresis, Female, Humans, Immunoblotting, Inbred BALB C, Matrix Metalloproteinase 1/genetics/*metabolism, Matrix Metalloproteinase 9/genetics/*metabolism, Mice, Neoplasm Metastasis/genetics/physiopathology, Polyacrylamide Gel, Proto-Oncogene Proteins c-myb/genetics/*metabolism, Real-Time Polymerase Chain Reaction, RNA, Small Interfering, Tumor},

pubstate = {published},

tppubtype = {article}

}

@article{benes_inhibition_2011,

title = {Inhibition of topoisomerase IIα: novel function of wedelolactone.},

author = {Petr Benes and Lucia Knopfova and Filip Trcka and Alice Nemajerova and Diana Pinheiro and Karel Soucek and Miroslav Fojta and Jan Smarda},

doi = {10.1016/j.canlet.2011.01.002},

issn = {1872-7980 0304-3835},

year  = {2011},

date = {2011-04-01},

journal = {Cancer letters},

volume = {303},

number = {1},

pages = {29–38},

abstract = {The naturally occurring coumestan wedelolactone has been previously shown to reduce growth of various cancer cells. So far, the growth-suppressing effect of wedelolactone has been attributed to the inhibition of the NFκB transcription factor and/or androgen receptors. We found that wedelolactone suppressed growth and induced apoptosis of androgen receptor-negative MDA-MB-231 breast cancer cells at concentrations that did not inhibit the NFκB activity. The cells responded to wedelolactone by the S and G2/M phase cell cycle arrest and induction of the DNA damage signaling. Wedelolactone interacted with dsDNA and inhibited the activity of DNA topoisomerase IIα. We conclude that wedelolactone can act as growth suppressor independently of NFκB and androgen receptors.},

note = {Place: Ireland},

keywords = {Antigens, Antineoplastic Agents/pharmacology, Apoptosis/drug effects, Breast Neoplasms/*drug therapy/enzymology/pathology, Cell Cycle/drug effects, Cell Growth Processes/drug effects, Cell Line, Cell Survival/drug effects, Coumarins/*pharmacology, DNA Damage, DNA Topoisomerases, DNA-Binding Proteins/*antagonists & inhibitors/metabolism, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoblotting, Neoplasm/metabolism, Signal Transduction, Topoisomerase Inhibitors/*pharmacology, Tumor, Type II/metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{soucek_growthdifferentiation_2010,

title = {Growth/differentiation factor-15 is an abundant cytokine in human seminal plasma.},

author = {Karel Soucek and Eva Slabáková and Petra Ovesná and Alice Malenovská and Alois Kozubík and Ales Hampl},

doi = {10.1093/humrep/deq264},

issn = {1460-2350 0268-1161},

year  = {2010},

date = {2010-12-01},

journal = {Human reproduction (Oxford, England)},

volume = {25},

number = {12},

pages = {2962–2971},

abstract = {BACKGROUND: Transforming growth factor-β cytokines have various biological effects in female reproductive tissue, including modulation of inflammatory response and induction of immune tolerance to seminal antigens in the reproductive tract. However, no studies have analyzed the presence of growth/differentiation factor-15 (GDF-15/macrophage inhibitory cytokine-1) in seminal fluid or demonstrated the quantity and form of GDF-15, its possible role or the relationship between its concentration and semen quality. METHODS: The form and the concentration of GDF-15 were determined in 53 seminal plasma samples of both fertile and infertile men by ELISA and western blot. The sperm cells of three volunteers were treated with recombinant GDF-15, and cell viability and apoptosis were assessed by flow cytometry. The effect of GDF-15 on vaginal epithelial cells and peripheral blood mononuclear cells (PBMCs) was analyzed by quantitative RT-PCR. RESULTS: The GDF-15 concentration in seminal plasma ranged from 0.2 to 6.6 μg/ml as determined by ELISA. Western blot analysis revealed that GDF-15 is present in the active form. In vitro cultivation of sperm cells with GDF-15 did not affect their viability or rates of apoptosis; however, it did inhibit proliferation of PBMCs and induce expression of FOXP3 in CD4+CD25+ cells. CONCLUSIONS: To the best of our knowledge, this is the first demonstration that GDF-15 is an abundant cytokine in seminal plasma, although its concentration is not associated with semen quality or the fertility/infertility status of the donors. Moreover, our data show that GDF-15 displays immunosuppressive characteristics.},

note = {Place: England},

keywords = {Adult, Apoptosis/drug effects, CD4-Positive T-Lymphocytes/metabolism, Cell Proliferation/drug effects, Cell Survival/drug effects, Epithelial Cells/metabolism, Female, Forkhead Transcription Factors/biosynthesis, Growth Differentiation Factor 15/*physiology, Humans, Interleukin-2 Receptor alpha Subunit/metabolism, Leukocytes, Male, Middle Aged, Mononuclear/drug effects, Semen Analysis, Semen/*metabolism, Spermatozoa},

pubstate = {published},

tppubtype = {article}

}

@article{soucek_fetal_2010,

title = {Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation.},

author = {Karel Soucek and Pavla Gajdusková and Marie Brázdová and Martina Hýzd'alová and Lenka Kocí and David Vydra and Radek Trojanec and Zuzana Pernicová and Lenka Lentvorská and Marián Hajdúch and Jirina Hofmanová and Alois Kozubík},

doi = {10.1016/j.cancergencyto.2009.11.009},

issn = {1873-4456 0165-4608},

year  = {2010},

date = {2010-03-01},

journal = {Cancer genetics and cytogenetics},

volume = {197},

number = {2},

pages = {107–116},

abstract = {Stable cell lines obtained by spontaneous immortalization might represent early stages of malignant transformation and be useful experimental models for studies of mechanisms of cancer development. The FHC (fetal human cells) cell line has been established from normal fetal colonic mucosa. Detailed characterization of this cell line and mechanism of spontaneously acquired immortality have not been described yet. Therefore, we characterized the FHC cell line in terms of its tumorigenicity, cytogenetics, and TP53 gene mutation analysis. FHC cells displayed capability for anchorage-independent growth in semisolid media in vitro and formed solid tumors after transplantation into SCID (severe combined immunodeficiency) mice. This tumorigenic phenotype was associated with hypotriploidy and chromosome number ranging from 66 to 69. Results of comparative genetic hybridization arrays showed that most chromosomes included regions of copy number gains or losses. Region 8q23 approximately 8q24.3 (containing, e.g., MYC proto-oncogene) was present in more than 20 copies per nucleus. Moreover, we identified mutation of TP53 gene in codon 273; triplet CGT coding Arg was changed to CAG coding His. Expression of Pro codon 72 polymorphic variant of p53 was also detected. Mutation of TP53 gene was associated with abolished induction of p21(Waf1/Cip1) and MDM-2 proteins and resistance to apoptosis after genotoxic treatment. Because of their origin from normal fetal colon and their relative resistance to the induction of apoptosis, FHC cells can be considered a valuable experimental model for various studies.},

note = {Place: United States},

keywords = {*Genes, Animals, Apoptosis/physiology, Carcinoembryonic Antigen/metabolism, Cell Adhesion/physiology, Cell Growth Processes/physiology, Cell Line, Cell Transformation, Colon/cytology/metabolism/*physiology, Colonic Neoplasms/*genetics/*pathology, Comparative Genomic Hybridization, Cytogenetic Analysis/methods, DNA Damage, DNA Mutational Analysis/methods, Female, Fetus/cytology, Fluorescence, HCT116 Cells, Humans, In Situ Hybridization, Karyotyping, Keratins/metabolism, Mice, Neoplasm Transplantation, Neoplastic/genetics/pathology, p53, Phenotype, Proto-Oncogene Mas, SCID, Signal Transduction, Transformed},

pubstate = {published},

tppubtype = {article}

}

@article{kummer_estrogenic_2008,

title = {Estrogenic activity of environmental polycyclic aromatic hydrocarbons in uterus of immature Wistar rats.},

author = {Vladimír Kummer and Jarmila Masková and Zdenek Zralý and Jirí Neca and Pavlína Simecková and Jan Vondrácek and Miroslav Machala},

doi = {10.1016/j.toxlet.2008.06.862},

issn = {0378-4274},

year  = {2008},

date = {2008-08-01},

journal = {Toxicology letters},

volume = {180},

number = {3},

pages = {212–221},

abstract = {Polycyclic aromatic hydrocarbons (PAHs) are an important group of environmental pollutants, known for their mutagenic and carcinogenic activities. Many PAHs are aryl hydrocarbon receptor (AhR) ligands and several recent studies have suggested that PAHs or their metabolites may activate estrogen receptors (ER). The present study investigated possible estrogenic/antiestrogenic effects of abundant environmental contaminants benzo[a]pyrene (BaP), benz[a]anthracene (BaA), fluoranthene (Fla) and benzo[k]fluoranthene (BkF) in vivo, using the immature rat uterotrophic assay. The present results suggest that BaA, BaP and Fla behaved as estrogen-like compounds in immature Wistar rats, when applied for 3 consecutive days at 10mg/kg/day, as documented by a significant increase of uterine weight and hypertrophy of luminal epithelium. These effects were likely to be mediated by ERalpha, a major subtype of ER present in uterus, as they were inhibited by treatment with ER antagonist ICI 182,780. BaA, the most potent of studied PAHs, induced a significant estrogenic effect within a concentration range 0.1-50mg/kg/day; however, it did not reach the maximum level induced by reference estrogens. The proposed antiestrogenicity of the potent AhR agonist BkF was not confirmed in the present in vivo study; the exposure to BkF did not significantly affect the uterine weight, although a weak suppression of ERalpha immunostaining was observed in luminal and glandular epithelium, possibly related to its AhR-mediated activity. The PAHs under study did not induce marked genotoxic damage in uterine tissues, as documented by the lack of Ser-15-phoshorylated p53 protein staining. With the exception of Fla, all three remaining compounds increased CYP1-dependent monooxygenation activities in liver at the doses used, suggesting that the potential tissue-specific antiestrogenic effects of PAHs mediated by metabolization of 17beta-estradiol also cannot be excluded. Taken together, these environmentally relevant PAHs induced estrogenic effects in vivo, which might affect their toxic impact and carcinogenicity.},

note = {Place: Netherlands},

keywords = {Animals, Cytochrome P-450 CYP1A1/metabolism, Endocrine Disruptors/*toxicity, Environmental Pollutants/*toxicity, Epithelium/drug effects, Estradiol/metabolism, Estrogen Receptor alpha/metabolism, Estrogens/*biosynthesis, Female, Hydroxylation, Immunohistochemistry, Liver/drug effects/metabolism, Microsomes, Organ Size/drug effects, Ovary/drug effects, Phosphorylation, Polycyclic Aromatic Hydrocarbons/*toxicity, Rats, Tumor Suppressor Protein p53/metabolism, Uterus/drug effects/*metabolism, Wistar},

pubstate = {published},

tppubtype = {article}

}

@article{horvath_different_2007,

title = {Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.},

author = {Viktor Horváth and Karel Soucek and Lenka Svihálková-Sindlerová and Jan Vondrácek and Olga Blanárová and Jirina Hofmanová and Petr Sova and Alois Kozubík},

doi = {10.1007/s10637-007-9062-7},

issn = {0167-6997},

year  = {2007},

date = {2007-10-01},

journal = {Investigational new drugs},

volume = {25},

number = {5},

pages = {435–443},

abstract = {Platinum (IV) derivative with adamantylamine-LA-12-represents a new generation of highly efficient anti-cancer drug derived from cisplatin and is currently in the final stage of phase I clinical trials. Understanding the specific mechanisms of its effects on cell cycle is necessary for defining the mode of action of LA-12. In this study, we characterized the ability of LA-12 to induce cell cycle perturbations in ovarian cancer cell line A2780 as compared to equitoxic cisplatin treatment. LA-12 induced a permanent accumulation of A2780 cells in S phase while cisplatin caused G2/M arrest at 24-h time point, where we also detected an increased expression of Gadd45alpha protein. Although both derivatives induced a rapid increase of p53 expression, this was not associated with a down-regulation of Mdm2 protein. Increased expression of p21(Cip1/WAF1) protein and its association with cyclins A and B1 suggested that this cyclin-dependent kinase inhibitor might contribute significantly to the observed perturbations of cell cycle. The results of this study provide insight into the mechanism of action of platinum-based derivative with adamantylamine on cell cycle in ovarian cancer cells. The differences between effects of LA-12 and cisplatin suggest that more attention should be paid to elucidation of modes of action of novel platinum(IV) complexes at cellular level.},

note = {Place: United States},

keywords = {Amantadine/*analogs & derivatives/pharmacology, Antineoplastic Agents/*pharmacology, bcl-2-Associated X Protein/metabolism, Carcinoma/drug therapy/metabolism, Cell Cycle Proteins/metabolism, Cell Cycle/*drug effects, Cell Line, Cell Proliferation/drug effects, Cisplatin/*pharmacology, Female, Humans, Organoplatinum Compounds/*pharmacology, Ovarian Neoplasms/drug therapy/metabolism, Proto-Oncogene Proteins c-mdm2/metabolism, Tumor, Tumor Suppressor Protein p53/metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{horvath_platinumiv_2006,

title = {Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.},

author = {Viktor Horváth and Olga Blanárová and Lenka Svihálková-Sindlerová and Karel Soucek and Jirina Hofmanová and Petr Sova and Ales Kroutil and Peter Fedorocko and Alois Kozubík},

doi = {10.1016/j.ygyno.2005.11.016},

issn = {0090-8258},

year  = {2006},

date = {2006-07-01},

journal = {Gynecologic oncology},

volume = {102},

number = {1},

pages = {32–40},

abstract = {OBJECTIVES: The resistance of tumor cells to cisplatin remains a major cause of treatment failure in cancer patients. In this study, the ability of Pt(IV) complex with adamantylamine-LA-12 and its reduced counterpart with lower oxidation state Pt(II)-LA-9 to overcome intrinsic cisplatin resistance was investigated. METHODS: The ovarian adenocarcinoma SK-OV-3 cells were exposed to cisplatin, LA-9, or LA-12 for 72 h and the effects of drug concentrations that caused 10% or 50% inhibition of cell proliferation were determined. After 24-72 h of sustained exposure viability, apoptosis and inhibition of proliferation were analyzed. DNA synthesis and cell cycle analysis were performed simultaneously in order to determine the modulation of cell cycle after platinum complexes treatment. RESULTS: Lung Resistance-related Protein (LRP/MVP) was detected in SK-OV-3 cells but not in the other two ovarian cancer lines with different sensitivity to cisplatin. LRP/MVP overexpression may be an important factor contributing to intrinsic cisplatin resistance. Interestingly, Pt(IV) complex-LA-12 had approximately 2.7-fold lower IC(50) concentration than LA-9 or cisplatin in SK-OV-3 cells. Moreover, LA-12 caused persistent accumulation of cells in S-phase of the cell cycle while LA-9 and cisplatin treatment-induced S-phase arrest was transient and shifted to G(2)/M-phase at later intervals. Apoptosis seemed to be not the dominant type of cell death caused by such the derivatives, but it was the most intensive after LA-12 treatment. CONCLUSIONS: We found strong differences between effects of Pt(IV) complex-LA-12 and Pt(II) derivatives-LA-9 and cisplatin on cytokinetic parameters. Overall, LA-12 but not its reduced Pt(II) counterpart LA-9 is the compound effective in p53 null human ovarian cancer cells and it is able to overcome intrinsic cisplatin resistance in these cells.},

note = {Place: United States},

keywords = {Adenocarcinoma/*drug therapy/metabolism/pathology, Amantadine/administration & dosage/analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols/*pharmacology, Blotting, Cell Cycle/drug effects, Cell Growth Processes/drug effects, Cell Line, Cisplatin/administration & dosage, DNA, Drug resistance, Female, Humans, Neoplasm, Neoplasm Proteins/biosynthesis, Neoplasm/biosynthesis, Organoplatinum Compounds/administration & dosage/*pharmacology, Ovarian Neoplasms/*drug therapy/metabolism/pathology, Poly(ADP-ribose) Polymerases/metabolism, Tumor, Vault Ribonucleoprotein Particles/biosynthesis, Western},

pubstate = {published},

tppubtype = {article}

}

@article{kozubik_high_2005,

title = {High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.},

author = {Alois Kozubík and Viktor Horváth and Lenka Svihálková-Sindlerová and Karel Soucek and Jirina Hofmanová and Petr Sova and Ales Kroutil and Frantisek Zák and Adolf Mistr and Jaroslav Turánek},

doi = {10.1016/j.bcp.2004.09.005},

issn = {0006-2952},

year  = {2005},

date = {2005-02-01},

journal = {Biochemical pharmacology},

volume = {69},

number = {3},

pages = {373–383},

abstract = {[(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)], coded as LA-12, is an octahedral platinum(IV) complex containing a bulky hydrophobic ligand - adamantylamine. The use of bulky hydrophobic amines as non-leaving ligands, may increase uptake of the compound by the cancer cells. Therefore, the effects of LA-12 on sensitive (A2780) and cisplatin resistant (A2780cis) ovarian cancer cell lines were investigated and compared to those of cisplatin. IC(50) and IC(90) concentrations of LA-12 were 6- (A2780) or 18-fold (A2780cis) lower than those for cisplatin (MTT assay). Equitoxic concentrations (IC(50) or IC(90)) of both compounds caused a significant and similar time- and dose-dependent inhibition of cell proliferation and an increase in the number of floating cells which corresponded to the decrease of total cell viability. A different type and dynamics of cell cycle perturbation after cisplatin and LA-12 treatment were detected. Exposure to LA-12 resulted in transient accumulation of A2780 and A2780cis cells in S phase, while cisplatin caused G(2)/M arrest in sensitive and S phase arrest in resistant cells. A relatively low rate of apoptosis after exposure to IC(50) or IC(90) of both complexes was observed, markedly higher in resistant A2780cis cells. Western blot analysis indicated a concentration-dependent p53 level increase in both lines (higher after cisplatin treatment). PARP cleavage was observed only in A2780cis cells. In conclusion, LA-12 was found to be significantly more efficient than cisplatin, and it was able to overcome the acquired cisplatin resistance (showing resistance factor 2.84-fold lower than those for cisplatin). In spite of the low rate of apoptosis, LA-12 caused increase of p53 level and cell cycle perturbations in the ovarian cancer cell lines studied.},

note = {Place: England},

keywords = {Amantadine/*analogs & derivatives/*pharmacology, Antineoplastic Agents/*pharmacology, Cell Cycle/drug effects, Cell Line, Cell Proliferation/drug effects, Cisplatin/*pharmacology, DNA Fragmentation/drug effects, Drug resistance, Female, Humans, Neoplasm, Organoplatinum Compounds/*pharmacology, Ovarian Neoplasms/*drug therapy/pathology, Poly(ADP-ribose) Polymerases/analysis, Tumor, Tumor Suppressor Protein p53/analysis},

pubstate = {published},

tppubtype = {article}

}

@article{pliskova_deregulation_2005,

title = {Deregulation of cell proliferation by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells reflects both genotoxic and nongenotoxic events.},

author = {Martina Plísková and Jan Vondrácek and Borivoj Vojtesek and Alois Kozubík and Miroslav Machala},

doi = {10.1093/toxsci/kfi040},

issn = {1096-6080 1096-0929},

year  = {2005},

date = {2005-02-01},

journal = {Toxicological sciences : an official journal of the Society of Toxicology},

volume = {83},

number = {2},

pages = {246–256},

abstract = {Polycyclic aromatic hydrocarbons (PAHs), such as benzo[a]pyrene (BaP), are carcinogens suggested to be involved in development of human cancer. Several recent studies have reported that PAHs can activate estrogen receptors (ER), either directly or indirectly by producing estrogenic metabolites. We hypothesized that the activation of ER by PAHs or their metabolites could induce cell proliferation in estrogen-sensitive cells. In the present study, we found that two PAHs, benz[a]anthracene (BaA) and BaP, can stimulate proliferation of human breast carcinoma MCF-7 cells at concentrations 100 nM and higher. This effect was ER-dependent, because it was blocked by the pure antiestrogen ICI 182,780. Although both PAHs partially inhibited S-phase entry and DNA synthesis induced by 17beta-estradiol, they stimulated S-phase entry when applied to MCF-7 cells synchronized by serum deprivation. This was in contrast with model antiestrogenic aryl hydrocarbon receptor ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin, which fully suppressed S-phase entry. BaP, which is a strong mutagen, was found to induce p53 tumor suppressor expression, a partial S-phase arrest and at higher concentrations also cell death. Pifithrin-alpha, a synthetic inhibitor of p53 activity, abolished both S-phase arrest and apoptosis induced by genotoxic PAHs, and it potentiated the proliferative effect of BaP. Thus, both genotoxic and nongenotoxic events seem to interact in the effects of BaP on cell proliferation. Taken together, our data indicate that both BaA and BaP can stimulate cell proliferation through activation of ER. The proliferative effects of these carcinogenic compounds might contribute to tumor promotion in estrogen-sensitive tissues.},

note = {Place: United States},

keywords = {Benz(a)Anthracenes/*toxicity, Benzo(a)pyrene/*toxicity, Benzothiazoles, Breast Neoplasms/drug therapy/*genetics/metabolism, Bromodeoxyuridine/metabolism, Carcinogens/*toxicity, Carcinoma/drug therapy/*genetics/metabolism, Cell Cycle/drug effects, Cell Line, Cell Proliferation/*drug effects, Cell Survival/drug effects, DNA Replication/drug effects, Dose-Response Relationship, Drug, Drug Interactions, Epigenesis, Estradiol/*analogs & derivatives/pharmacology, Estrogen, Estrogen Antagonists/pharmacology, Female, Fulvestrant, Genetic, Humans, Receptors, Thiazoles/pharmacology, Toluene/*analogs & derivatives/pharmacology, Tumor, Tumor Suppressor Protein p53/antagonists & inhibitors/genetics/metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{kubala_perioperative_2002,

title = {Perioperative and postoperative course of cytokines and the metabolic activity of neutrophils in human cardiac operations and heart transplantation.},

author = {Lukás Kubala and Milan Cíz and Jan Vondrácek and Jan Cerný and Petr Nemec and Pavel Studeník and Hana Cizová and Antonín Lojek},

doi = {10.1067/mtc.2002.125814},

issn = {0022-5223},

year  = {2002},

date = {2002-12-01},

journal = {The Journal of thoracic and cardiovascular surgery},

volume = {124},

number = {6},

pages = {1122–1129},

abstract = {OBJECTIVES: The purpose of this study was to compare systemic inflammatory responses after heart transplantation and nontransplant cardiac operations, both involving cardiopulmonary bypass with a focus on the role of polymorphonuclear leukocytes. METHODS: Lipid peroxidation, blood phagocyte radical production, and interleukin 6, 8, and 10 plasma concentrations during surgical intervention and on the first and seventh postoperative days were evaluated in patients undergoing heart transplantation (n = 24) and in patients not undergoing transplantation (n = 30). RESULTS: Levels of interleukin 6, 8, and 10 increased in both groups of patients during early reperfusion. They normalized within the first postoperative day in the transplant group, whereas the nontransplant group's interleukin 6 and 8 levels remained increased on the seventh day after the operation. Interleukin 10 plasma levels were higher in the heart transplant group during reperfusion. Lipid peroxidation was increased after the operation in both groups of patients. Phagocyte activity was enhanced at reperfusion and at all other sampling times only in the nontransplant group. On the other hand, phagocyte activity oscillated around the preoperative level during heart transplantation, or it was even decreased. CONCLUSION: Both cardiac operations involving heart transplantation and those without transplantation are associated with increased oxidative stress and an enhanced production of proinflammatory and anti-inflammatory cytokines. Differences in interleukin 10 production and phagocyte activity could be caused mainly by the immunosuppressive therapy in heart transplant operations.},

note = {Place: United States},

keywords = {*Cardiac Surgical Procedures, *Heart Transplantation, Cardiopulmonary Bypass, Cytokines/*metabolism, Female, Humans, Interleukin-10/metabolism, Interleukin-6/metabolism, Interleukin-8/metabolism, Male, Middle Aged, Neutrophils/*metabolism, oxidative stress, Phagocytosis, Time Factors},

pubstate = {published},

tppubtype = {article}

}